RESUMEN
BACKGROUND: Pediatric living-donor liver transplantation (LDLT) candidates often receive long-term antibiotic treatment. Micafungin has been used as an antifungal agent after LDLT, but the adequate dose after pediatric LDLT was unknown. Here, we report micafungin blood concentrations after pediatric LDLT and discuss its safety and adequate dosing. METHODS: Pediatric patients with data on micafungin concentrations after LDLT were identified. Those with surgical complications were excluded. All patients received standard tacrolimus-based immunosuppression. A micafungin dose of 1 mg/kg was administered once daily for 10 days starting on postoperative day (POD) 1. The trough and peak micafungin blood concentrations were evaluated on PODs 1, 4, 7, and 10. Beta D glucan levels and liver function tests were assessed to determine micafungin effectiveness and safety. RESULTS: Ten patients were enrolled, with a median age of 1.2 years. The median graft vs body weight ratio was 2.7%. The primary diseases were biliary atresia (n = 7), Alagille syndrome (n = 2), and progressive familial intrahepatic cholestasis type 2 (n = 1). Mean peak micafungin levels were 4.47, 6.27, 5.47, and 5.47 µg/mL on PODs 1, 4, 7, and 10, respectively. Mean trough levels were 2.03, 1.88, and 2.66 µg/mL on PODs 4, 7, and 10, respectively. The micafungin half-lives were 13.7, 14.7, and 14.0 hours on PODs 4, 7, and 10, respectively. Beta D glucan levels were 4.4 pg/mL and 3.7 pg/mL before and after transplantation, respectively, indicating no significant difference (P = .3). No clinical fungal infections were observed. CONCLUSION: Micafungin administration is safe and effective after pediatric LDLT.
Asunto(s)
Antifúngicos , Trasplante de Hígado , Donadores Vivos , Micafungina , Humanos , Micafungina/uso terapéutico , Micafungina/administración & dosificación , Antifúngicos/uso terapéutico , Antifúngicos/sangre , Masculino , Femenino , Lactante , Preescolar , Niño , Inmunosupresores/uso terapéutico , Inmunosupresores/sangre , Inmunosupresores/farmacocinética , Inmunosupresores/administración & dosificación , Lipopéptidos/farmacocinética , Lipopéptidos/uso terapéutico , Lipopéptidos/administración & dosificaciónRESUMEN
PURPOSE: Echinocandins are favored drugs for the treatment of fungal infections. There is growing evidence that obese patients treated with echinocandins have lower exposures due to pharmacokinetic (PK) alterations. We conducted a scoping review to characterize, evaluate, and summarize the available evidence on echinocandins exposures in obese patients. SUMMARY: A comprehensive search of PubMed, Embase, and Cochrane Library for studies on echinocandins published from database inception to October 28, 2022, was conducted using PRISMA-ScR methodology. A total of 25 studies comprising more than 3,174 subjects (8 micafungin studies, 7 caspofungin studies, 9 anidulafungin studies, and 1 rezafungin study) were included in this review. Seventeen studies reported lower echinocandins exposures in overweight and obese individuals compared with normal-weight individuals; the authors of these studies recommended dose adjustments. Conversely, 8 studies did not find significant differences in echinocandin exposure among subjects in varying body weight categories. Clinicians may consider dose adjustments of echinocandins in obese patients; however, there is limited evidence on the ideal dose adjustment strategy to overcome the low echinocandins exposures in obese patients. CONCLUSION: This scoping review shed light on a growing body of evidence indicating that obese patients have lower echinocandin exposures relative to targeted PK indices, which may lead to negative therapeutic implications. Currently, a lack of high-quality evidence impedes reaching consensus on recommendations for echinocandin dosing adjustment in obese patients. Future research evaluating the optimal echinocandin dosing strategy for obese patients is needed.
Asunto(s)
Antifúngicos , Equinocandinas , Humanos , Antifúngicos/uso terapéutico , Peso Corporal , Equinocandinas/efectos adversos , Equinocandinas/farmacocinética , Lipopéptidos/farmacocinética , Lipopéptidos/uso terapéutico , Pruebas de Sensibilidad Microbiana , Obesidad/tratamiento farmacológico , SobrepesoRESUMEN
PURPOSE: Reduced exposure to echinocandins has been reported in specific patient populations, such as critically ill patients; however, fixed dosing strategies are still used. The present review examines the accumulated evidence supporting echinocandin therapeutic drug monitoring (TDM) and summarizes available assays and sampling strategies. METHODS: A literature search was conducted using PubMed in December 2020, with search terms such as echinocandins, anidulafungin, caspofungin, micafungin, or rezafungin with pharmacology, pharmacokinetics (PKs), pharmacodynamics (PDs), drug-drug interactions, TDM, resistance, drug susceptibility testing, toxicity, adverse drug reactions, bioanalysis, chromatography, and mass spectrometry. Data on PD/PD (PK/PD) outcome markers, drug resistance, PK variability, drug-drug interactions, assays, and TDM sampling strategies were summarized. RESULTS: Echinocandins demonstrate drug exposure-efficacy relationships, and maximum concentration/minimal inhibitory concentration ratio (Cmax/MIC) and area under the concentration-time curve/MIC ratio (AUC/MIC) are proposed PK/PD markers for clinical response. The relationship between drug exposure and toxicity remains poorly clarified. TDM could be valuable in patients at risk of low drug exposure, such as those with critical illness and/or obesity. TDM of echinocandins may also be useful in patients with moderate liver impairment, drug-drug interactions, hypoalbuminemia, and those undergoing extracorporeal membrane oxygenation, as these conditions are associated with altered exposure to caspofungin and/or micafungin. Assays are available to measure anidulafungin, micafungin, and caspofungin concentrations. A limited-sampling strategy for anidulafungin has been reported. CONCLUSIONS: Echinocandin TDM should be considered in patients at known risk of suboptimal drug exposure. However, for implementing TDM, clinical validation of PK/PD targets is needed.
Asunto(s)
Antifúngicos , Mycobacterium tuberculosis , Antifúngicos/efectos adversos , Monitoreo de Drogas/métodos , Equinocandinas/efectos adversos , Humanos , Lipopéptidos/efectos adversos , Lipopéptidos/farmacocinética , Pruebas de Sensibilidad MicrobianaRESUMEN
Containment of the COVID-19 pandemic requires reducing viral transmission. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is initiated by membrane fusion between the viral and host cell membranes, which is mediated by the viral spike protein. We have designed lipopeptide fusion inhibitors that block this critical first step of infection and, on the basis of in vitro efficacy and in vivo biodistribution, selected a dimeric form for evaluation in an animal model. Daily intranasal administration to ferrets completely prevented SARS-CoV-2 direct-contact transmission during 24-hour cohousing with infected animals, under stringent conditions that resulted in infection of 100% of untreated animals. These lipopeptides are highly stable and thus may readily translate into safe and effective intranasal prophylaxis to reduce transmission of SARS-CoV-2.
Asunto(s)
COVID-19/transmisión , Lipopéptidos/administración & dosificación , Fusión de Membrana/efectos de los fármacos , SARS-CoV-2/efectos de los fármacos , Inhibidores de Proteínas Virales de Fusión/administración & dosificación , Internalización del Virus/efectos de los fármacos , Administración Intranasal , Animales , COVID-19/prevención & control , COVID-19/virología , Chlorocebus aethiops , Modelos Animales de Enfermedad , Diseño de Fármacos , Hurones , Lipopéptidos/química , Lipopéptidos/farmacocinética , Lipopéptidos/farmacología , Ratones , Profilaxis Pre-Exposición , SARS-CoV-2/aislamiento & purificación , SARS-CoV-2/fisiología , Glicoproteína de la Espiga del Coronavirus/metabolismo , Distribución Tisular , Células Vero , Inhibidores de Proteínas Virales de Fusión/química , Inhibidores de Proteínas Virales de Fusión/farmacocinética , Inhibidores de Proteínas Virales de Fusión/farmacologíaRESUMEN
The insulin-like peptide human relaxin-2 was identified as a hormone that, among other biological functions, mediates the hemodynamic changes occurring during pregnancy. Recombinant relaxin-2 (serelaxin) has shown beneficial effects in acute heart failure, but its full therapeutic potential has been hampered by its short half-life and the need for intravenous administration limiting its use to intensive care units. In this study, we report the development of long-acting potent single-chain relaxin peptide mimetics. Modifications in the B-chain of relaxin, such as the introduction of specific mutations and the trimming of the sequence to an optimal size, resulted in potent, structurally simplified peptide agonists of the relaxin receptor Relaxin Family Peptide Receptor 1 (RXFP1) (e.g., 54). Introduction of suitable spacers and fatty acids led to the identification of single-chain lipidated peptide agonists of RXFP1, with sub-nanomolar activity, high subcutaneous bioavailability, extended half-lives, and in vivo efficacy (e.g., 64).
Asunto(s)
Lipopéptidos/farmacología , Receptores Acoplados a Proteínas G/agonistas , Receptores de Péptidos/agonistas , Relaxina/análogos & derivados , Relaxina/farmacología , Secuencia de Aminoácidos , Animales , Enfermedades Cardiovasculares , Línea Celular Tumoral , Células HEK293 , Semivida , Humanos , Lipopéptidos/genética , Lipopéptidos/farmacocinética , Masculino , Simulación de Dinámica Molecular , Estructura Molecular , Mutación , Subunidades de Proteína , Ratas Sprague-Dawley , Relaxina/genética , Relación Estructura-ActividadRESUMEN
OBJECTIVE: Arterial thrombosis leading to ischemic injury worsens the prognosis of many patients with cardiovascular disease. PZ-128 is a first-in-class pepducin that reversibly inhibits PAR1 (protease-activated receptor 1) on platelets and other vascular cells by targeting the intracellular surface of the receptor. The TRIP-PCI (Thrombin Receptor Inhibitory Pepducin in Percutaneous Coronary Intervention) trial was conducted to assess the safety and efficacy of PZ-128 in patients undergoing cardiac catheterization with intent to perform percutaneous coronary intervention. Approach and Results: In this randomized, double-blind, placebo-controlled, phase 2 trial, 100 patients were randomly assigned (2:1) to receive PZ-128 (0.3 or 0.5 mg/kg), or placebo in a 2-hour infusion initiated just before the start of cardiac catheterization, on top of standard oral antiplatelet therapy. Rates of the primary end point of bleeding were not different between the combined PZ-128 doses (1.6%, 1/62) and placebo group (0%, 0/35). The secondary end points of major adverse coronary events at 30 and 90 days did not significantly differ but were numerically lower in the PZ-128 groups (0% and 2% in the PZ-128 groups, 6% and 6% with placebo, p=0.13, p=0.29, respectively). In the subgroup of patients with elevated baseline cardiac troponin I, the exploratory end point of 30-day major adverse coronary events + myocardial injury showed 83% events in the placebo group versus 31% events in the combined PZ-128 drug groups, an adjusted relative risk of 0.14 (95% CI, 0.02-0.75); P=0.02. CONCLUSIONS: In this first-in-patient experience, PZ-128 added to standard antiplatelet therapy appeared to be safe, well tolerated, and potentially reduced periprocedural myonecrosis, thus providing the basis for further clinical trials. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02561000.
Asunto(s)
Síndrome Coronario Agudo/terapia , Plaquetas/efectos de los fármacos , Cateterismo Cardíaco , Péptidos de Penetración Celular/administración & dosificación , Enfermedad de la Arteria Coronaria/terapia , Lipopéptidos/administración & dosificación , Miocardio/patología , Intervención Coronaria Percutánea , Inhibidores de Agregación Plaquetaria/administración & dosificación , Receptor PAR-1/agonistas , Trombosis/prevención & control , Síndrome Coronario Agudo/diagnóstico por imagen , Anciano , Plaquetas/metabolismo , Cateterismo Cardíaco/efectos adversos , Cateterismo Cardíaco/instrumentación , Péptidos de Penetración Celular/efectos adversos , Péptidos de Penetración Celular/farmacocinética , Enfermedad de la Arteria Coronaria/diagnóstico por imagen , Método Doble Ciego , Femenino , Humanos , Infusiones Intravenosas , Lipopéptidos/efectos adversos , Lipopéptidos/farmacocinética , Masculino , Persona de Mediana Edad , Necrosis , Intervención Coronaria Percutánea/efectos adversos , Intervención Coronaria Percutánea/instrumentación , Inhibidores de Agregación Plaquetaria/efectos adversos , Inhibidores de Agregación Plaquetaria/farmacocinética , Prueba de Estudio Conceptual , Estudios Prospectivos , Receptor PAR-1/metabolismo , Recurrencia , Stents , Trombosis/sangre , Trombosis/etiología , Factores de Tiempo , Resultado del Tratamiento , Estados UnidosRESUMEN
Increased usage of daptomycin to treat infections caused by Gram-positive bacterial pathogens has resulted in emergence of resistant mutants. In a search for more effective daptomycin analogues through medicinal chemistry studies, we found that methylation at the nonproteinogenic amino acid kynurenine in daptomycin could result in significant enhancement of antibacterial activity. Termed "kynomycin," this new antibiotic exhibits higher antibacterial activity than daptomycin and is able to eradicate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) strains, including daptomycin-resistant strains. The improved antimicrobial activity of kynomycin was demonstrated in in vitro time-killing assay, in vivo wax worm model, and different mouse infection models. The increased antibacterial activity, improved pharmacokinetics, and lower cytotoxicity of kynomycin, compared to daptomycin, showed the promise of the future design and development of next-generation daptomycin-based antibiotics.
Asunto(s)
Antibacterianos/uso terapéutico , Depsipéptidos/uso terapéutico , Lipopéptidos/uso terapéutico , Infecciones Estafilocócicas/tratamiento farmacológico , Animales , Antibacterianos/síntesis química , Antibacterianos/farmacocinética , Antibacterianos/toxicidad , Permeabilidad de la Membrana Celular/efectos de los fármacos , Daptomicina/química , Daptomicina/uso terapéutico , Depsipéptidos/síntesis química , Depsipéptidos/farmacocinética , Depsipéptidos/toxicidad , Farmacorresistencia Bacteriana/efectos de los fármacos , Enterococcus/efectos de los fármacos , Femenino , Células HEK293 , Humanos , Lepidópteros/efectos de los fármacos , Lepidópteros/microbiología , Lipopéptidos/síntesis química , Lipopéptidos/farmacocinética , Lipopéptidos/toxicidad , Masculino , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Metilación , Ratones Endogámicos BALB C , Ratones Endogámicos ICR , Pruebas de Sensibilidad MicrobianaRESUMEN
The effects of oxytocin on food intake and body weight reduction have been demonstrated in both animal models and human clinical studies. Despite being efficacious, oxytocin is enzymatically unstable and thus considered to be unsuitable for long-term use in patients with obesity. Herein, a series of oxytocin derivatives were engineered through conjugation with fatty acid moieties that are known to exhibit high binding affinities to serum albumin. One analog (OT-12) in particular was shown to be a potent full agonist at the oxytocin receptor (OTR) in vitro with good selectivity and long half-life (24 h) in mice. Furthermore, OT-12 is peripherally restricted, with very limited brain exposure (1/190 of the plasma level). In a diet-induced obesity mouse model, daily subcutaneous administration of OT-12 exhibited more potent anorexigenic and body weight reducing effects than carbetocin. Thus, our results suggest that the long-acting, peripherally restricted OTR agonist may offer potential therapeutic benefits for obesity.
Asunto(s)
Fármacos Antiobesidad/uso terapéutico , Depresores del Apetito/uso terapéutico , Lipopéptidos/uso terapéutico , Oxitocina/análogos & derivados , Oxitocina/uso terapéutico , Receptores de Oxitocina/agonistas , Animales , Fármacos Antiobesidad/síntesis química , Fármacos Antiobesidad/farmacocinética , Depresores del Apetito/síntesis química , Depresores del Apetito/farmacocinética , Peso Corporal/efectos de los fármacos , Humanos , Lipopéptidos/síntesis química , Lipopéptidos/farmacocinética , Masculino , Ratones Endogámicos BALB C , Obesidad/tratamiento farmacológico , Oxitocina/farmacocinética , Ingeniería de Proteínas , Pérdida de Peso/efectos de los fármacosRESUMEN
RNA interference is a relatively new tool used to silence specific genes in diverse biological systems. The development of this promising new technique for research and therapeutic use in studying and treating neurological diseases has been hampered by the lack of an efficient way to deliver siRNA transvascularly across the blood-brain barrier (BBB) to the central nervous system (CNS). Here we describe the generation of three different liposomal siRNA delivery vehicles to the CNS using the thin film hydration method. Utilizing cationic or anionic liposomes protects the siRNA from serum nucleases and proteases en route. To deliver the siRNA specifically to the CNS, the liposomes are complexed to a peptide that acts as a neuronal address by binding to nicotinic acetylcholine receptors (nAchRs). When injected intravenously, these liposome-siRNA-peptide complexes (LSPCs) or peptide addressed liposome encapsulated therapeutic siRNA (PALETS) resist serum degradation, effectively cross the BBB and deliver siRNA to AchR-expressing cells to suppress protein expression in the CNS.
Asunto(s)
Barrera Hematoencefálica/metabolismo , Técnicas de Transferencia de Gen , Lipopéptidos/farmacocinética , Neuronas/metabolismo , Animales , Cationes/química , Cationes/farmacocinética , Lipopéptidos/química , Liposomas , Ratones , Interferencia de ARN , ARN Interferente Pequeño/genéticaRESUMEN
Cytosolic delivery of functional siRNA remains the major challenge to develop siRNA-based therapeutics. Designing clinically safe and effective siRNA transporter to deliver functional siRNA across the plasma and endosomal membrane remains a key hurdle. With the aim of improving endosomal release, we have designed cyclic and linear peptide-based transporters having an Arg-DHis-Arg template. Computational studies show that the Arg-DHis-Arg template is also stabilized by the Arg-His side-chain hydrogen bonding interaction at physiological pH, which dissociates at lower pH. The overall atomistic interactions were examined by molecular dynamics simulations, which indicate that the extent of peptide_siRNA assembly formation depends greatly on physicochemical properties of the peptides. Our designed peptides having the Arg-DHis-Arg template and two lipidic moieties facilitate high yield of intracellular delivery of siRNA. Additionally, unsaturated lipid, linoleic acid moieties were introduced to promote fusogenicity and facilitate endosomal release and cytosolic delivery. Interestingly, such protease-resistant peptides provide serum stability to siRNA and exhibit high efficacy of erk1 and erk2 gene silencing in the triple negative breast cancer (TNBC) cell line. The peptide having two linoleyl moieties demonstrated comparable efficacy with commercial transfection reagent HiPerFect, as evidenced by the erk1 and erk2 gene knockdown experiment. Additionally, our study shows that ERK1/2 silencing siRNA and doxorubicin-loaded gramicidin-mediated combination therapy is more effective than siRNA-mediated gene silencing-based monotherapy for TNBC treatment.
Asunto(s)
Antineoplásicos/farmacocinética , Péptidos de Penetración Celular/farmacocinética , Sistemas de Liberación de Medicamentos/métodos , Lipopéptidos/farmacocinética , ARN Interferente Pequeño/farmacocinética , Neoplasias de la Mama Triple Negativas/metabolismo , Antineoplásicos/síntesis química , Antineoplásicos/química , Antineoplásicos/farmacología , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Péptidos de Penetración Celular/síntesis química , Péptidos de Penetración Celular/química , Péptidos de Penetración Celular/farmacología , Humanos , Lipopéptidos/síntesis química , Lipopéptidos/química , Lipopéptidos/farmacología , ARN Interferente Pequeño/química , ARN Interferente Pequeño/genética , ARN Interferente Pequeño/farmacología , Transducción de Señal/efectos de los fármacosRESUMEN
AIM: To develop a simple and robust LC-MS/MS method to quantify concentrations of micafungin in human plasma for pharmacokinetic studies and therapeutic drug monitoring. METHODS: Sample preparation involved protein precipitation with acetonitrile:methanol (83:17% v/v) and [13C6]-micafungin as internal standard. A rapid and selective method for micafungin was validated across a range of 0.200-10.0 mg/l. RESULTS: The calculated accuracy for the eight-point calibration ranged from 0.7 to 5.3%. Within-run precision ranged from 0.8 to 5.9%, between-run precision ranged from 0.7 to 3.1%, and overall precision ranged from 1.3 to 6.6%. CONCLUSION: A simple and robust LC-MS/MS method for analyzing micafungin in human plasma has been validated and was utilized for quantification of micafungin.
Asunto(s)
Cromatografía Liquida/métodos , Monitoreo de Drogas/métodos , Equinocandinas/sangre , Equinocandinas/farmacocinética , Lipopéptidos/sangre , Lipopéptidos/farmacocinética , Espectrometría de Masas en Tándem/métodos , Métodos Analíticos de la Preparación de la Muestra , Humanos , MicafunginaRESUMEN
The aim of this study was to develop a proliposomal formulation of lipopeptide antibiotic drug daptomycin (DAP) for oral delivery. Thin film hydration was the selected method for preparation of proliposomes. Different phospholipids including soy-phosphatidylcholine (SPC), hydrogenated egg-phosphatidylcholine (HEPC), and distearoyl-phosphatidylcholine (DSPC) were evaluated in combination with cholesterol. The inclusion of surface charge modifiers in the formulation such as dicetyl phosphate (DCP) and stearylamine (SA) to enhance drug encapsulation was also evaluated. Particle size, surface charge, and encapsulation efficiency were performed on daptomycin-hydrated proliposomes as part of physical characterization. USP type II dissolution apparatus with phosphate buffer (pH 6.8) was used for in vitro drug release studies. Optimized formulation was evaluated for in vivo pharmacokinetics after oral administration to Sprague-Dawley rats. Proliposomes composed of SPC exhibited higher entrapment efficiency than those containing HEPC or DSPC. The highest entrapment efficiency was achieved by positively charged SPC-SA proliposomes, showing an encapsulation efficiency of 92% and a zeta potential of + 28 mV. In vitro drug release of optimized formulation demonstrated efficient drug retention totaling for less than 20% drug release within the first 60 min and only 42% drug release after 2 h. Pharmacokinetic parameters after single oral administration of optimized proliposomal formulation indicated a significant increase in oral bioavailability of DAP administered as SPC-SA proliposomes when compared to drug solution. Based on these results, incorporation of charge modifiers into proliposomes may increase drug loading and proliposomes an attractive carrier for oral delivery of daptomycin.
Asunto(s)
Daptomicina/administración & dosificación , Daptomicina/farmacocinética , Sistemas de Liberación de Medicamentos/métodos , Lipopéptidos/administración & dosificación , Lipopéptidos/farmacocinética , Administración Oral , Animales , Antibacterianos/administración & dosificación , Antibacterianos/química , Antibacterianos/farmacocinética , Disponibilidad Biológica , Daptomicina/química , Portadores de Fármacos/administración & dosificación , Portadores de Fármacos/química , Portadores de Fármacos/farmacocinética , Liberación de Fármacos , Lipopéptidos/química , Liposomas , Masculino , Tamaño de la Partícula , Fosfatidilcolinas/administración & dosificación , Fosfatidilcolinas/química , Fosfatidilcolinas/farmacocinética , Ratas , Ratas Sprague-DawleyRESUMEN
BACKGROUND: Dosing in obese critically ill patients is challenging due to pathophysiological changes derived from obesity and/or critical illness, and it remains fully unexplored. This study estimated the micafungin probability of reaching adequate 24-h area under the curve (AUC0-24h)/minimum inhibitory concentration (MIC) values against Candida spp. for an obese/nonobese, critically ill/noncritically ill, large population. METHODS: Blood samples for pharmacokinetic analyses were collected from 10 critically ill nonobese patients, 10 noncritically ill obese patients, and 11 critically ill morbidly obese patients under empirical/directed micafungin treatment. Patients received once daily 100-150 mg micafungin at the discretion of the treating physician following the prescribing information and hospital guidelines. Total micafungin concentrations were determined by high-performance liquid chromatography (HPLC). Monte-Carlo simulations were performed and the probability of target attainment (PTA) was calculated using the AUC0-24/MIC cut-offs 285 (C. parapsilosis), 3000 (all Candida spp.), and 5000 (nonparapsilosis Candida spp.). Intravenous once-daily 100-mg, 150-mg, and 200-mg doses were simulated at different body weights (45, 80, 115, 150, and 185 kg) and age (30, 50, 70 and 90 years old). PTAs ≥ 90% were considered optimal. Fractional target attainment (FTA) was calculated using published MIC distributions. A dosing regimen was considered successful if the FTA was ≥ 90%. RESULTS: Overall, 100 mg of micafungin was once-daily administered for nonobese and obese patients with body mass index (BMI) ≤ 45 kg/m2 and 150 mg for morbidly obese patients with BMI > 45 kg/m2 (except two noncritically ill obese patients with BMI ~ 35 kg/m2 receiving 150 mg, and one critically ill patient with BMI > 45 kg/m2 receiving 100 mg). Micafungin concentrations in plasma were best described using a two-compartment model. Weight and age (but not severity score) were significant covariates and improved the model. FTAs > 90% were obtained against C. albicans with the 200 mg/24 h dose for all body weights (up to 185 kg), and with the 150 mg/24 h for body weights < 115 kg, and against C. glabrata with the 200 mg/24 h dose for body weights < 115 kg. CONCLUSION: The lack of adequacy for the 100 mg/24 h dose suggested the need to increase the dose to 150 mg/24 h for C. albicans infections. Further pharmacokinetic/pharmacodynamic studies should address optimization of micafungin dosing for nonalbicans Candida infections.
Asunto(s)
Candidiasis/tratamiento farmacológico , Relación Dosis-Respuesta a Droga , Equinocandinas/farmacología , Equinocandinas/farmacocinética , Lipopéptidos/farmacología , Lipopéptidos/farmacocinética , Obesidad Mórbida/fisiopatología , Obesidad/fisiopatología , Adulto , Anciano , Anciano de 80 o más Años , Antifúngicos/farmacocinética , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Área Bajo la Curva , Índice de Masa Corporal , Enfermedad Crítica/terapia , Equinocandinas/uso terapéutico , Femenino , Humanos , Lipopéptidos/uso terapéutico , Masculino , Micafungina , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Método de Montecarlo , Curva ROC , EspañaRESUMEN
Myrcludex B acts as a hepatitis B and D virus entry inhibitor blocking the sodium taurocholate cotransporting polypeptide (SLC10A1). We investigated the effects of myrcludex B on plasma bile acid disposition, tenofovir pharmacokinetics, and perpetrator characteristics on cytochrome P450 (CYP) 3A. Twelve healthy volunteers received 300 mg tenofovir disoproxil fumarate orally and 10 mg subcutaneous myrcludex B. Myrcludex B increased total plasma bile acid exposure 19.2-fold without signs of cholestasis. The rise in conjugated bile acids was up to 124-fold (taurocholic acid). Coadministration of tenofovir with myrcludex B revealed no relevant changes in tenofovir pharmacokinetics. CYP3A activity slightly but significantly decreased by 29% during combination therapy. Myrcludex B caused an asymptomatic but distinct rise in plasma bile acid concentrations and had no relevant impact on tenofovir pharmacokinetics. Changes in CYP3A activity might be due to alterations in bile acid signaling. Long-term effects of elevated bile acids will require critical evaluation.
Asunto(s)
Antivirales/administración & dosificación , Ácidos y Sales Biliares/sangre , Lipopéptidos/administración & dosificación , Inhibidores de la Transcriptasa Inversa/farmacocinética , Tenofovir/farmacocinética , Administración Oral , Adulto , Antivirales/efectos adversos , Antivirales/farmacocinética , Biomarcadores/sangre , Citocromo P-450 CYP3A/metabolismo , Interacciones Farmacológicas , Femenino , Humanos , Inyecciones Subcutáneas , Lipopéptidos/efectos adversos , Lipopéptidos/farmacocinética , Masculino , Persona de Mediana Edad , Transportadores de Anión Orgánico Sodio-Dependiente/antagonistas & inhibidores , Transportadores de Anión Orgánico Sodio-Dependiente/metabolismo , Estudios Prospectivos , Inhibidores de la Transcriptasa Inversa/administración & dosificación , Inhibidores de la Transcriptasa Inversa/efectos adversos , Medición de Riesgo , Simportadores/antagonistas & inhibidores , Simportadores/metabolismo , Tenofovir/administración & dosificación , Tenofovir/efectos adversos , Regulación hacia Arriba , Adulto JovenRESUMEN
Invasive candidiasis is common and often fatal in patients supported with extracorporeal membrane oxygenation (ECMO), and treatment relies on optimal antifungal dosing. The ECMO circuit can extract drug and decrease drug exposure, placing the patient at risk of therapeutic failure. This ex vivo study determined the extraction of antifungal drugs by the ECMO circuit. Fluconazole and micafungin were studied separately in three closed-loop circuit configurations to isolate the impact of the oxygenator, hemofilter, and tubing on circuit extraction. Each circuit was primed with human blood, and flow was set to 1 L/min. Drug was dosed to achieve therapeutic concentrations. Each antifungal was added to a separate tube of blood to serve as a control. Serial blood samples were collected over 24 hours and concentrations were quantified with a validated assay. Drug recovery was calculated at each time point: (C t /C i )*100, with C t and C i the concentrations at time = t and 1 minute, respectively. After 24 hours of recirculation, mean recovery of fluconazole in the ECMO circuit (95-98%) and controls (101%) was high. In contrast, mean recovery of micafungin was dependent on the time and circuit configuration. Recovery at 4 hours was only 46% when a hemofilter was in-line but was much higher when the hemofilter was removed (91%). By 24 hours, however, micafungin recovery was low in all circuit configurations (26-43%), regardless of the presence of a hemofilter, as well as in the controls (57%). In conclusion, these results suggest that micafungin is extracted by the ECMO circuit, which may result in decreased drug exposure in vivo.
Asunto(s)
Candidiasis/tratamiento farmacológico , Equinocandinas/administración & dosificación , Oxigenación por Membrana Extracorpórea/métodos , Fluconazol/administración & dosificación , Lipopéptidos/administración & dosificación , Tiempo de Circulación Sanguínea , Candidiasis/sangre , Relación Dosis-Respuesta a Droga , Equinocandinas/farmacocinética , Oxigenación por Membrana Extracorpórea/instrumentación , Fluconazol/farmacocinética , Hemofiltración/instrumentación , Hemofiltración/métodos , Humanos , Lipopéptidos/farmacocinética , Micafungina , Unión Proteica , Albúmina Sérica/metabolismoRESUMEN
We compared the micafungin killing rate and postantifungal effect (PAFE) at 4, 16 and 32 mg/L in RPMI- 1640 and in 50% serum against the C. albicans complex. In RPMI-1640 PAFEs were 1.5 - >19.4, 9.7 - >20.1 and 15.9 - >18.5 hours for C. albicans, C. africana and C. dubliniensis, respectively. In 50% serum PAFEs decreased sharply to 0-1.7 hours for all three species; killing rates were always negative. Short growth inhibition without killing in 50% serum suggests that micafungin PAFE has a limited role in the eradication of the C. albicans complex from the bloodstream.
Asunto(s)
Antifúngicos/farmacología , Equinocandinas/farmacocinética , Lipopéptidos/farmacocinética , Candida/efectos de los fármacos , Candida albicans/efectos de los fármacos , Humanos , Micafungina , Pruebas de Sensibilidad Microbiana , Factores de TiempoRESUMEN
The estimated attributable mortality rate for invasive candidiasis (IC) in the intensive care unit (ICU) setting varies from 30 to 40%. Physiological changes in critically ill patients may affect the distribution and elimination of micafungin, and therefore, dosing adjustments might be mandatory. The objective of this study was to determine the pharmacokinetic parameters of micafungin in critically ill patients and assess the probability of target attainment. Micafungin plasma concentrations were measured to estimate the pharmacokinetic properties of micafungin. MIC values for Candida isolates were determined to assess the probability of target attainment for patients. Data from 19 patients with suspected or proven invasive candidiasis were available for analysis. The median area under the concentration-time curve from 0 to 24 h at steady state (AUC0-24) was 89.6 mg · h/liter (interquartile range [IQR], 75.4 to 113.6 mg · h/liter); this was significantly lower than the median micafungin AUC0-24 values of 152.0 mg · h/liter (IQR, 136.0 to 162.0 mg · h/liter) and 134.0 mg · h/liter (IQR, 118.0 to 148.6 mg · h/liter) in healthy volunteers (P = <0.0001 and P = <0.001, respectively). All Candida isolates were susceptible to micafungin, with a median MIC of 0.016 mg/liter (IQR, 0.012 to 0.023 mg/liter). The median AUC0-24/MIC ratio was 5,684 (IQR, 4,325 to 7,578), and 3 of the 17 evaluable patients (17.6%) diagnosed with proven invasive candidiasis did not meet the AUC/MIC ratio target of 5,000. Micafungin exposure was lower in critically ill patients than in healthy volunteers. The variability in micafungin exposure in this ICU population could be explained by the patients' body weight. Our findings suggest that healthier patients (sequential organ failure assessment [SOFA] score of <10) weighing more than 100 kg and receiving 100 mg micafungin daily are at risk for inappropriate micafungin exposure and potentially inadequate antifungal treatment. (This study has been registered at ClinicalTrials.gov under identifier NCT01716988.).
Asunto(s)
Antifúngicos/farmacocinética , Candida albicans/efectos de los fármacos , Candida glabrata/efectos de los fármacos , Candidiasis Invasiva/tratamiento farmacológico , Equinocandinas/farmacocinética , Lipopéptidos/farmacocinética , Anciano , Antifúngicos/sangre , Área Bajo la Curva , Disponibilidad Biológica , Peso Corporal , Candida albicans/crecimiento & desarrollo , Candida glabrata/crecimiento & desarrollo , Candidiasis Invasiva/sangre , Candidiasis Invasiva/microbiología , Candidiasis Invasiva/patología , Estudios de Casos y Controles , Enfermedad Crítica , Cálculo de Dosificación de Drogas , Equinocandinas/sangre , Femenino , Humanos , Unidades de Cuidados Intensivos , Lipopéptidos/sangre , Masculino , Micafungina , Pruebas de Sensibilidad Microbiana , Persona de Mediana EdadRESUMEN
Candida species are a part of the human microbiome and can cause systemic infection upon immune suppression. Candida glabrata infections are increasing and have greater rates of antifungal resistance than other species. Here, we present a C. glabrata gastrointestinal (GI) colonization model to explore whether colonized yeast exposed to caspofungin, an echinocandin antifungal, develop characteristic resistance mutations and, upon immunosuppression, breakthrough causing systemic infection. Daily therapeutic dosing (5 mg/kg of body weight) of caspofungin resulted in no reduction in fecal burdens, organ breakthrough rates similar to control groups, and resistance rates (0 to 10%) similar to those reported clinically. Treatment with 20 mg/kg caspofungin initially reduced burdens, but a rebound following 5 to 9 days of treatment was accompanied by high levels of resistance (FKS1/FKS2 mutants). Although breakthrough rates decreased in this group, the same FKS mutants were recovered from organs. In an attempt to negate drug tolerance that is critical for resistance development, we cotreated mice with daily caspofungin and the chitin synthase inhibitor nikkomycin Z. The largest reduction (3 log) in GI burdens was obtained within 3 to 5 days of 20 mg/kg caspofungin plus nikkomycin treatment. Yet, echinocandin resistance, characterized by a novel Fks1-L630R substitution, was identified following 5 to 7 days of treatment. Therapeutic caspofungin plus nikkomycin treatment left GI burdens unchanged but significantly reduced organ breakthrough rates (20%; P < 0.05). Single-dose pharmacokinetics demonstrated low levels of drug penetration into the GI lumen posttreatment with caspofungin. Overall, we show that C. glabrata echinocandin resistance can arise within the GI tract and that resistant mutants can readily disseminate upon immunosuppression.
Asunto(s)
Antifúngicos/farmacología , Candida glabrata/efectos de los fármacos , Candidiasis/tratamiento farmacológico , Equinocandinas/farmacología , Proteínas Fúngicas/genética , Tracto Gastrointestinal/efectos de los fármacos , Glucosiltransferasas/genética , Lipopéptidos/farmacología , Aminoglicósidos/farmacología , Animales , Antifúngicos/farmacocinética , Candida glabrata/genética , Candida glabrata/crecimiento & desarrollo , Candidiasis/inmunología , Candidiasis/microbiología , Caspofungina , Quitina Sintasa/antagonistas & inhibidores , Quitina Sintasa/genética , Quitina Sintasa/metabolismo , Dexametasona/efectos adversos , Modelos Animales de Enfermedad , Esquema de Medicación , Farmacorresistencia Fúngica/genética , Tolerancia a Medicamentos/genética , Equinocandinas/farmacocinética , Femenino , Proteínas Fúngicas/metabolismo , Tracto Gastrointestinal/inmunología , Tracto Gastrointestinal/microbiología , Glucosiltransferasas/metabolismo , Humanos , Inmunosupresores/efectos adversos , Isoenzimas/genética , Isoenzimas/metabolismo , Lipopéptidos/farmacocinética , Ratones , Pruebas de Sensibilidad Microbiana , MutaciónRESUMEN
Polyglutamine (PolyQ) diseases are progressive neurodegenerative disorders caused by both protein- and RNA-mediated toxicities. We previously showed that a peptidyl inhibitor, P3, which binds directly to expanded CAG RNA can inhibit RNA-induced nucleolar stress and suppress RNA-induced neurotoxicity. Here we report a N-acetylated and C-amidated derivative of P3, P3V8, that showed a more than 20-fold increase in its affinity for expanded CAG RNA. The P3V8 peptide also more potently alleviated expanded RNA-induced cytotoxicity in vitro, and suppressed polyQ neurodegeneration in Drosophila with no observed toxic effects. Further N-palmitoylation of P3V8 (L1P3V8) not only significantly improved its cellular uptake and stability, but also facilitated its systemic exposure and brain uptake in rats via intranasal administration. Our findings demonstrate that concomitant N-acetylation, C-amidation and palmitoylation of P3 significantly improve both its bioactivity and pharmacological profile. L1P3V8 possesses drug/lead-like properties that can be further developed into a lead inhibitor for the treatment of polyQ diseases.
Asunto(s)
Encéfalo/metabolismo , Trastornos Heredodegenerativos del Sistema Nervioso/genética , Lipopéptidos/farmacocinética , ARN/genética , Expansión de Repetición de Trinucleótido/genética , Animales , Animales Modificados Genéticamente , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/genética , Drosophila melanogaster , Células HEK293 , Trastornos Heredodegenerativos del Sistema Nervioso/metabolismo , Humanos , Lipopéptidos/metabolismo , Lipopéptidos/farmacología , Masculino , Péptidos/genética , Péptidos/metabolismo , ARN/metabolismo , Ratas Sprague-DawleyRESUMEN
OBJECTIVES: Echinocandins are the newest addition of the last decade to the antifungal armamentarium, which, owing to their unique mechanism of action, selectively target the fungal cells without affecting mammalian cells. Since the time of their introduction, they have come to occupy an important niche in the antifungal pharmacotherapy, due to their efficacy, safety, tolerability and favourable pharmacokinetic profiles. This review deals with the varying facets of echinocandins such as their chemistry, in-vitro and in-vivo evaluations, clinical utility and indications, pharmacokinetic and pharmacodynamic profiles, and pharmacoeconomic considerations. KEY FINDINGS: Clinical studies have demonstrated that the echinocandins - caspofungin, micafungin and anidulafungin - are equivalent, if not superior, to the mainstay antifungal therapies involving amphotericin B and fluconazole. Moreover, echinocandin regimen has been shown to be more cost-effective and economical. Hence, the echinocandins have found favour in the management of invasive systemic fungal infections. CONCLUSIONS: The subtle differences in echinocandins with respect to their pharmacology, clinical therapy and the mechanisms of resistance are emerging at a rapid pace from the current pool of research which could potentially aid in extending their utility in the fungal infections of the eye, heart and nervous system.